126 results about "Microbacterium" patented technology

The invention discloses a preparation method and application of athlete-derived bifidobacterium probiotics for intestinal barrier repair, and relates to the technical field of biochemistry and microorganisms, and the preparation method comprises the steps of special bacteria source sampling, directional separation and purification, molecular biological identification, antibiotic sensitivity evaluation and injury repair verification. According to the preparation method and application of the sportsman-derived bifidobacterium probiotics for repairing the intestinal barrier, the sportsman intestinal flora is used as an exclusive bacterial source, and the unique metabolic elite attribute and stress adaptability of the sportsman intestinal flora are utilized to directionally screen and obtain a bifidobacterium strain adaptive to an extreme physiological stress environment; the bottleneck that conventional probiotics are only suitable for a common physiological environment and the survival rate and activity in a stress state are greatly reduced is broken through, high survival rate and metabolic activity can be kept in extreme environments such as exercise heat stress and the like, and accurate repair of intestinal barriers is realized through multiple mechanisms; meanwhile, an exclusive screening, identification and safety evaluation system is established, so that the safety and functional specificity of the strain are ensured.

A microbial gene editing scheme automatic design method, system and storage medium; the method comprises: selecting a design object for different types of strains, the design object is bacteria or fungi; after determining the target gene, obtaining the target gene information from the NCBI database; the design scheme of bacteria comprises the following steps: determining the gRNA design region; selecting the optimal gRNA sequence; doing sequence complexity and GC content analysis; the design scheme of fungi uses a frameshift scheme: the gRNA of the frameshift scheme is set at any position not overlapping with other genes after the start codon in the gene; select gRNA sequence in gRNA design region, select the optimal gRNA sequence; design two pairs of four primer sequences for homologous arm identification primer; this scheme can replace the complicated and time-consuming manual scheme, save a lot of time, solve the problem of high cost in the design of the best site and the design of sgRNA sequence scheme of artificial gene knockout.

This invention relates to the fields of microbial genetic engineering and fermentation biomanufacturing technology, specifically disclosing a recombinant Corynebacterium glutamicum with high 5-aminolevulinic acid (ALA) production and its applications. Addressing the problems of existing strains such as crude enzyme activity regulation, inhibited cell growth, the need for external inhibitors, and low yield, this invention uses Corynebacterium glutamicum as a host and removes the gdhA gene without scarring to reduce precursor competitive metabolism. Site-directed mutations of the endogenous hemB gene (S288A, D128E, R231K) are performed to moderately reduce dehydratase activity. A high-expression plasmid pXMJ19-hemA containing the hemA gene from Rhodopsinus capsulatum is constructed and introduced into the modified strain to obtain a recombinant strain with optimized triple metabolism. This strain reduces product degradation without the need for external dehydratase inhibitors, does not affect cell growth, and achieves a yield up to 4.30 times higher than the control after 42 hours of fermentation, with ALA accumulation exceeding 8.9 g / L. The strain exhibits stable characteristics, the process is simple, and it has good industrial application value.

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The application discloses a gene editing system CRISPR-Cas12p and application thereof. Based on microbial genomes and metagenomic data, the CRISPR-Cas12p protein of the CRISPR-Cas protein family is obtained by preliminary screening by using a Prodigal gene prediction tool, a Pfam database and HMMER software, and a gene editing system CRISPR-Cas12p is constructed. PAM preference and interference function identification show that the editing system has a PAM preference of 5'-TTC-3', can effectively realize targeted cutting by using long transcripts and double RNA hybrid chain transcripts respectively, and can realize editing of a target gene in prokaryotic and eukaryotic cells. The CRISPR-Cas12p gene editing system obtained by the application has a small protein component, is beneficial to delivery, can realize gene editing in prokaryotic and eukaryotic cells, and has a wide application prospect.

This invention discloses a high-yield lactyl-3-4 ...5-4-4-4-4-4- N This invention relates to plasmid-free genetically engineered strains of tetrasaccharides and their applications, belonging to the field of microbial genetic engineering. The invention screened strains with higher activity. β -1,3-galactosyltransferase gene PmgalT Computer-aided enzyme function modification was used to achieve a shake-flask yield of 10.05 g / L for the constructed mutant. Subsequently, genome integration was performed... breast Multi-copy integration PmgalT * V27I / V39I / Y147F ‑galE‑galU A plasmid-free strain was constructed, enabling it to grow in shake flasks with lactoyl- N The yield of tetrasaccharides reached 14.4 g / L. Using glucose as the sole carbon source, the highest yield of 68.19 g / L was achieved at 64.5 h; using glycerol as the sole carbon source, the highest yield of 62.88 g / L was achieved at 60.5 h, providing a basis for its industrial production.

This invention discloses a methanogenic lyase homologous to PeiR lyase and its applications. The PeiR lyase protein, targeting the peptide bonds of the methanogenic cell wall, participates in the biological process of hydrolyzing the archaea cell wall, effectively killing methanogens and reducing methane production. Proteins homologous to this lyase possess potential methane-reducing potential. This invention utilizes a series of bioinformatics software to identify protein sequences encoded by methanogenic viruses from a large amount of rumen microbial virome sequencing data, and analyzes the structural homology between these proteins and PeiR. Ultimately, this invention successfully obtained a series of methanogenic lyases homologous to PeiR. To achieve the expression of these lyases, this invention designed multiple primers to synthesize the target sequences and successfully expressed them in a prokaryotic expression system. In vitro gas production experiments with the crude enzyme solution showed that these lyases are effective in reducing methane production.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The present disclosure relates, in general terms, to directed evolution, and more specifically to compositions and methods for phage-assisted directed evolution in microbes. In one embodiment, there is provided a method for directed molecular evolution, the method comprising: a) introducing a propagation-defective phage vector into a first host cell (mutagenic host) competent to propagate the phage vector, wherein the first host cell comprises a gene construct of interest (GOI) to be evolved; and wherein the phage vector allows for (i) expression of an error-prone DNA polymerase in the first host cell for mutagenesis, and (ii) replication and packaging of the GOI into infectious phage particles; b) incubating the first host cell under conditions for replication and mutagenesis of the GOI and release of phage particles comprising mutated GOIs; c) infecting a second host cell (selection host) with phage particles from step b); and d) selecting for a desirable function of the GOI in the second host cell.

The present application belongs to the field of genetic engineering and microbial fermentation technology, and particularly relates to a recombinant Escherichia coli for producing N-acetylglucosamine as well as a construction method and application thereof. The present application takes Escherichia coli as a chassis, knocks out the nagDCABE gene cluster, the manXYZ gene cluster and the serA gene of the genome of the Escherichia coli, and introduces the glmS, GNA1 and serA genes into the Escherichia coli through a vector for expression. The yield of the Escherichia coli for fermenting GlcNAc provided by the present application can reach more than 100 g / L.

The invention relates to a Pseudomonas plecoglossicida pldB gene deletion mutant strain and a preparation method and application thereof, and belongs to the technical field of microorganisms and the field of algae preservation, the pldB gene of the mutant strain is deleted or inactivated, the nucleotide sequence of the pldB gene is shown as SEQ ID NO: 1, and the GenBank accession number of the Pseudomonas plecoglossicida is CP031146.1. The virulence of the mutant strain is obviously reduced compared with that of a wild strain of pseudomonas plecoglossicida; the strain can induce appropriate immune response of a host and up-regulate expression of anti-inflammatory factors, is beneficial to relieving immune pathological injury, has good attenuated live vaccine potential, and provides a brand new vaccine candidate strain for prevention and control of the visceral white-spot disease of the large yellow croaker.

This invention belongs to the field of microbial technology and relates to a thermoresistant, high-esterase-producing *Changfangluode* yeast and its specific identification method. The high-esterase-producing, thermoresistant *Changfangluode* yeast (… Lodderomyces elongisporus FBKL2.9-G53, deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC M 20253046 on December 29, 2025, exhibits excellent thermostability, maintaining good growth activity and enzyme production capacity even at 45℃. Quantitative esterase analysis showed a significant thermo-enhancing effect on enzyme production, with esterase activity of 12.83 U / mL at 28℃, increasing to 14.87 U / mL at 40℃ and 20.56 U / mL at 45℃. Simulated fermentation experiments further confirmed that the strain demonstrated robust metabolic adaptability under 45℃ heat stress, with esterase activity reaching 7.44±0.35 U / mL on day 7 of fermentation, approximately 1.55 times higher than the control group at 28℃.

本发明涉及微生物菌肥技术领域，特别是涉及一种菌酶复合微生物菌剂及其制备方法和应用。本发明针对田间秸秆还田腐解慢、影响下茬作物生长的问题，提供了一种菌酶复合微生物菌剂。所述菌酶复合微生物菌剂由草酸青霉（Penicillium oxalicum）菌株F12的孢子悬液与裂解性多糖单加氧酶（LPMO）按特定配比复配而成。田间施用时，将秸秆粉碎抛撒后，通过无人机喷洒菌剂，翻压入土，并调节土壤相对湿度。本发明解决了秸秆腐解慢的技术难题，有助于促进种子出苗和减少病虫害发生，可在秸秆还田场景和菌剂生产企业中推广应用。

This application discloses a recombinant bacterial strain that highly expresses nonspecific peroxygenase, its construction method, and its applications, relating to the field of microbial engineering technology. The strain of this invention uses *Escherichia coli* BL21(DE3) as the host. First, the key gene *hemA* for heme synthesis is integrated into the genome using the CRISPR-transposon system. Then, a chassis engineered strain A2 with 2 copies of optimal integration is screened and co-transformed with the rDcaUPO-A161C expression plasmid and the molecular chaperone plasmid pG-KJE8. The intracellular heme level of this strain is increased by 2.84 times compared to the original strain, and the total enzyme activity of rDcaUPO-A161C is cumulatively increased by 8.9 times and the specific enzyme activity is increased by 6.21 times compared to the wild type. This fundamentally solves the problems of insufficient cofactors, low folding efficiency, and poor activity in heterologous expression of nonspecific peroxygenases, and can be used for the efficient production of nonspecific peroxygenases.

The present application relates to the field of bioengineering and microbial technology, and relates to a yeast surface display construction method of a double-enzyme system. AGA1 The gene promoter is replaced by a strong constitutive promoter TEF1 and a glucose-responsive promoter HXT7 ; a double-enzyme free expression vector containing a galactose-inducible promoter GAL1 driven detoxification enzyme gene is constructed, and is transformed into a modified chassis cell to obtain a double-enzyme co-display engineering bacterium; the chassis protein AGA1 is expressed in a culture medium, and YtdepA and YtdepB are induced in a galactose-induced culture medium, so that the YtdepA and YtdepB are co-displayed on the yeast surface through the coupling mechanism of AGA1-AGA2. The strong constitutive promoter TEF1 and the glucose-repressed promoter HXT7 are coupled with the galactose-inducible promoter GAL1 respectively, so that the chassis protein and the detoxification enzyme are matched in the expression timing and intensity, and the detoxification enzyme is displayed on the yeast surface.

This invention relates to the field of probiotic screening and application technology, specifically to a Bifidobacterium adolescentis HC2916 that inhibits melanin synthesis, its microbial preparations, and applications. Bifidobacterium adolescentis HC2916 was deposited on May 16, 2023, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 27352. This strain exhibits excellent antioxidant capacity, capable of scavenging various free radicals and inhibiting lipid peroxidation. Furthermore, its fermentation supernatant and lysate significantly downregulate the protein and mRNA expression of MITF, a core factor in melanin production signaling, and inhibit the expression of its downstream key enzymes TYRP1 and TYRP2. This effectively suppresses UVA-induced increases in melanin content in skin keratinocytes, demonstrating promising application prospects in the field of skin whitening.

This invention discloses a strain of *Pediococcus pentosaceus* RL-10 and its application in bio-acidification rice soaking and bacterial cellulose production, belonging to the field of microbial technology. The preservation number of *Pediococcus pentosaceus* RL-10 is CCTCC NO: M 20252428. This invention is the first to use *Pediococcus pentosaceus* as a strain for bio-acidification rice soaking. Using rice soaking water as a production substrate, *Acetobacter Hansenulatus* and strain RL-10 are co-cultured in situ to produce bacterial cellulose loaded with antimicrobial peptides. Under certain process conditions, acidification of rice soaking by strain RL-10 can rapidly increase acidity and shorten soaking time. The bacterial cellulose production process of this invention is simple and low-cost; verification shows that the bacterial cellulose prepared by the method of this invention has high yield and good antibacterial activity, meeting the requirements of large-scale industrial production.

This invention provides a fully human anti-H3N2 virus neutralizing antibody IAV-3 and its applications, belonging to the fields of microbiology and immunology. The amino acid sequence of the heavy chain variable region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:2; the amino acid sequence of the heavy chain constant region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:3, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:4. The neutralizing antibody provided by this invention has the characteristics of high expression, fully human origin, and good stability, making it suitable for industrial production and possessing potential application value in responding to current and future influenza caused by the H3N2 virus.

This invention discloses *Bifidobacterium longum* with anti-aging functions and its applications, belonging to the field of microbial technology. The *Bifidobacterium longum* BBS 02 provided by this invention can promote cell vitality and proliferation, inhibit the high activity of β-galactosidase in senescent cells, and inhibit the high expression of the cyclin-dependent kinase inhibitor gene Cdkn1a, thereby achieving an anti-aging effect. The *Bifidobacterium longum* BBS 02 can be used to prepare edible nutrients or skin nutrients.

This invention relates to the fields of molecular cloning and protein expression, and particularly to a Pichia pastoris engineered strain expressing full-length human type III collagen and its applications. The engineered Pichia pastoris strain is obtained by cloning the enzymatically digested human type III collagen gene sequence into an expression vector to obtain a recombinant expression vector, which is then transformed into Pichia pastoris. This engineered Pichia pastoris strain was deposited at the China General Microbiological Culture Collection Center (CGMCC) on November 6, 2024, with accession number CGMCC NO.32510. The Pichia pastoris engineered strain obtained by this invention can efficiently produce the desired human type III collagen through fermentation, exhibiting excellent characteristics such as high yield and absence of endotoxins.

This invention relates to the fields of transcription factor engineering and metabolic engineering, and discloses an engineered strain that produces L-isoleucine, its construction method, and its applications. This strain... E. coli K12, MG1655 ( E. coli A1) serves as the host, integrating the subunit of the host factor IHF. ihfβ, ihfα Natural promoter replaced with P trc Strong promoters enable IHF overexpression, resulting in engineered bacteria. E. coli IHF4. This invention also discloses the construction steps of this strain, as well as its application method for L-isoleucine production by inoculating it into a fermentation medium, culturing it at 36-38℃ and 200 r / min for 40-60 h, and adjusting the pH and supplementing sugar. This engineered strain increases the yield of L-isoleucine by 42.11% compared to the starting strain. The construction method is simple and suitable for industrial microbial fermentation production of L-isoleucine.

Genetically engineered bacteria which express RNAs or proteins that produce ammonia upon decreases in phosphate concentrations are disclosed.

This invention discloses primers, kits, methods, and applications for detecting pathogenic *Pseudomonas proteus* strains based on the *oprL* gene, belonging to the field of microbial detection technology. This invention provides specific primers for detecting pathogenic *P. proteus* strains based on the *oprL* gene. The primers are designed based on the differential patterns identified after multiple sequence alignment, specifically by analyzing the results of multiple sequence alignments of all *P. proteus* *oprL* gene sequences in the NCBI database. The nucleotide sequences of the primers are shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3. The *oprL* gene of *P. proteus* is amplified by PCR, and the PCR amplification products are then subjected to electrophoresis. The pathogenicity of *P. proteus* can be effectively distinguished based on the electrophoresis image, enabling rapid detection of *P. proteus* infecting large yellow croaker. The primers have good specificity, and the detection method is simple and intuitive.

The application belongs to the field of agricultural biotechnology and microbial engineering technology, and particularly relates to a biosynthesis gene cluster of cystobactamids and application. The nucleotide sequence of the biosynthesis gene cluster is shown as SEQ ID NO:1. The application discloses a novel biological function of cystobactamids except for antibiotics, broadens the application scene, and has a good development prospect in the field of agricultural biological control.

The application provides a Saccharomyces cerevisiae for fermentative production of riboflavin, a microbial inoculum, a fermentation method and application thereof, and relates to the field of microbial fermentation. The application provides a Saccharomyces cerevisiae XF-GT, with a preservation number of CCTCC NO: M20242498, which has been preserved in the China Center for Type Culture Collection on November 11, 2024. The application adopts the Saccharomyces cerevisiae XF-GT for fermentative production of riboflavin, optimizes carbon sources and nitrogen sources, and combines with medium feeding culture to make the riboflavin yield reach 45.97 g / L after 96 h of fermentation, and the conversion rate reach 12.47%, so that the fermentation production method has high yield, stable process and is beneficial to industrial production.

This invention discloses a novel application of Bifidobacterium breve CCFM1078 in relieving intestinal colic, belonging to the fields of microbial technology and pharmaceutical technology. The Bifidobacterium breve CCFM1078 provided by this invention can relieve intestinal colic in infants and young children, specifically in the following ways: (1) increasing the visceral pain threshold and reducing the frequency of defecation in rats to a certain extent; (2) reducing the number of chromaffin cells and 5-HT content in the colon of rats with intestinal colic; (3) reducing the serum TNF-α and IL-1β content in rats with intestinal colic; (4) reducing the hippocampal TNF-α and IL-6 content in rats with intestinal colic; and (5) increasing the propionic acid content in the cecal contents of rats with intestinal colic.